Ventric Health Launches Redesigned Website to Advance Earlier Heart Failure Detection

Ventric Health Launches Redesigned Website to Advance Earlier Heart Failure Detection.

Ventric Health, maker of the Vivio System, the only FDA-cleared non-invasive device for measuring elevated left ventricular end-diastolic pressure in an outpatient setting, announced the launch of its renovated website at www.ventrichealth.com.

The updated site deepens clinical and operational content for primary care physicians, cardiologists, Medicare ACOs, and health systems working to close the heart failure diagnosis gap.

Enhanced Digital Resources and Content Architecture

New and enhanced features include an expanded Resources Hub with peer-reviewed research and workflow guidance, role-specific content tracks for clinical and administrative leaders, a stage-by-stage breakdown of heart failure progression, a streamlined demo request experience outlining what to expect from a 45-minute session, and deeper content on the Vivio System's real-world implementation, including a robust library of FAQs.

The role-specific content tracks recognize that clinical decision-makers and administrative leaders evaluate medical devices through different frameworks, physicians focus on diagnostic accuracy and clinical workflow integration, while administrators prioritize reimbursement, implementation costs, and population health metrics.

"This new website reflects our commitment to giving healthcare systems the information they need to act on heart failure earlier," said Dr. Thomas Cheek, Chief Medical Officer at Ventric Health.

The Stakes of Late Diagnosis

Heart failure remains severely underdiagnosed. Approximately 65 percent of at-risk patients receive their first diagnosis in the ER or inpatient setting, an average of 30 months after symptom onset. Late-stage management costs $21,800 per patient annually versus $4,300 when caught early. Shifting heart failure detection into primary care settings produces improvements in survival, quality of life, and healthcare expenditures.

The 30-month diagnostic delay represents a critical window during which myocardial remodeling progresses, symptoms worsen, and intervention opportunities narrow. The cost differential between early and late-stage management reflects not only direct medical expenses but also hospitalizations, specialist referrals, and advanced therapies required once heart failure reaches symptomatic stages.

Vivio System Technology and Clinical Workflow

Vivio measures left ventricular end-diastolic pressure non-invasively using a physics-based analysis of cardiac pressure and volume waveforms. The test completes in under five minutes at the point of care—no imaging, no referral, no invasive procedures. It pairs objective physiologic data with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) for a complete clinical picture.

The five-minute test duration positions Vivio within typical primary care appointment constraints, enabling incorporation into annual wellness visits, chronic disease management appointments, or opportunistic screening during encounters for other conditions. The non-invasive approach eliminates the barriers associated with echocardiography referrals including scheduling delays, patient compliance challenges, and reimbursement complexities.

Published Clinical Evidence

Published evidence includes a 2025 multicenter JAHA validation study, a 2025 HFSA abstract on pre-symptomatic Stage A detection, and a JACC Advances study on primary care screening. The multicenter validation provides external confirmation of diagnostic performance beyond single-site studies, while the Stage A detection research addresses the earliest phase of heart failure where intervention has maximum impact.

The JACC Advances primary care screening study represents particularly relevant evidence for the target audience, demonstrating feasibility and clinical utility in the exact setting where Ventric Health aims to deploy the technology.

Market Context and Competitive Positioning

The redesigned website launch occurs as healthcare systems face increasing pressure to identify heart failure earlier while managing costs and improving quality metrics. Medicare Shared Savings Program ACOs and value-based care contracts create financial incentives for preventing costly heart failure hospitalizations, aligning organizational economics with earlier detection strategies.

Ventric Health positions Vivio as addressing a gap in the diagnostic pathway between symptom-based clinical assessment (which lacks sensitivity for early-stage disease) and invasive catheterization (which provides definitive diagnosis but carries procedural risks inappropriate for population screening). The point-of-care model eliminates referral friction that causes diagnostic delays in traditional echocardiography pathways.

About Ventric Health

Ventric Health operates as a medical device company dedicated to earlier heart failure detection at the point of care. The Vivio System is trusted by leading health systems, Medicare ACOs, and primary care organizations across the United States. The company is headquartered in Pasadena, California.

Vivio is currently only available in the United States. The website provides access to clinical evidence, implementation resources, and demonstration requests at www.ventrichealth.com.

Related Stories